1Stanford Cancer Institute.
2Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
J Natl Compr Canc Netw. 2024 Jun;22(2 D). doi: 10.6004/jnccn.2024.0030.
Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Referral to specialized centers with expertise in the management of mastocytosis and multidisciplinary collaboration with subspecialists (eg, allergists for the management of anaphylaxis and drug hypersensitivities, anesthesiologists for invasive procedures or surgery, high-risk obstetrician for pregnancy) is recommended. The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.
肥大细胞增多症是一组异质性疾病,包括皮肤肥大细胞增多症、系统性肥大细胞增多症和肥大细胞瘤肉瘤。它与多种与肥大细胞介质释放和肥大细胞组织浸润相关的症状有关。建议向具有肥大细胞增多症管理专业知识的专业中心转诊,并与多学科专家(例如,过敏专家管理过敏反应和药物超敏反应、麻醉师进行侵入性操作或手术、高危产科医生进行妊娠)进行多学科合作。NCCN 系统性肥大细胞增多症指南为系统性肥大细胞增多症患者的诊断和综合治疗提供了基于证据和共识的建议。多学科专家组每年至少召开一次会议,审查内部和外部实体对指南的请求更改,并讨论现有和新疗法的数据。这些 NCCN 指南洞察重点介绍了指南的一些最新更新。